Loading...

We've got a brand new version of Simply Wall St! Try it out

NanoViricides

AMEX:NNVC
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NNVC
AMEX
$8M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
  • NanoViricides has significant price volatility in the past 3 months.
NNVC Share Price and Events
7 Day Returns
-9.9%
AMEX:NNVC
0.8%
US Biotechs
1.3%
US Market
1 Year Returns
-65.2%
AMEX:NNVC
16.4%
US Biotechs
19.4%
US Market
NNVC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NanoViricides (NNVC) -9.9% -4.5% -47.6% -65.2% -91.1% -96.3%
US Biotechs 0.8% 8.9% 16% 16.4% 23% -0.5%
US Market 1.3% 2.6% 5% 19.4% 37.3% 48%
1 Year Return vs Industry and Market
  • NNVC underperformed the Biotechs industry which returned 16.4% over the past year.
  • NNVC underperformed the Market in United States of America which returned 19.4% over the past year.
Price Volatility
NNVC
Industry
5yr Volatility vs Market
Related Companies

Value

 Is NanoViricides undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for NanoViricides. This is due to cash flow or dividend data being unavailable. The share price is $2.09.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NanoViricides's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NanoViricides's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AMEX:NNVC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-2.21
AMEX:NNVC Share Price ** AMEX (2019-12-13) in USD $2.09
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 18.79x
United States of America Market PE Ratio Median Figure of 2,927 Publicly-Listed Companies 18.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NanoViricides.

AMEX:NNVC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:NNVC Share Price ÷ EPS (both in USD)

= 2.09 ÷ -2.21

-0.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NanoViricides is loss making, we can't compare its value to the US Biotechs industry average.
  • NanoViricides is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does NanoViricides's expected growth come at a high price?
Raw Data
AMEX:NNVC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 33 Publicly-Listed Biotechs Companies 1.3x
United States of America Market PEG Ratio Median Figure of 2,040 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NanoViricides, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NanoViricides's assets?
Raw Data
AMEX:NNVC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $2.37
AMEX:NNVC Share Price * AMEX (2019-12-13) in USD $2.09
United States of America Biotechs Industry PB Ratio Median Figure of 417 Publicly-Listed Biotechs Companies 3.28x
United States of America Market PB Ratio Median Figure of 5,096 Publicly-Listed Companies 1.79x
AMEX:NNVC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:NNVC Share Price ÷ Book Value per Share (both in USD)

= 2.09 ÷ 2.37

0.88x

* Primary Listing of NanoViricides.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NanoViricides is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess NanoViricides's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. NanoViricides has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NanoViricides expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NanoViricides has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NanoViricides expected to grow at an attractive rate?
  • Unable to compare NanoViricides's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare NanoViricides's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare NanoViricides's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
AMEX:NNVC Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 21.5%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AMEX:NNVC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AMEX:NNVC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
AMEX:NNVC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 -7 -8
2019-06-30 -7 -8
2019-03-31 -9 -8
2018-12-31 -8 -8
2018-09-30 -7 -8
2018-06-30 -8 -9
2018-03-31 -5 -9
2017-12-31 -6 -10
2017-09-30 -7 -9
2017-06-30 -8 -10
2017-03-31 -8 -9
2016-12-31 -9 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if NanoViricides is high growth as no earnings estimate data is available.
  • Unable to determine if NanoViricides is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AMEX:NNVC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from NanoViricides Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:NNVC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
AMEX:NNVC Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -2.21
2019-06-30 -2.35
2019-03-31 -2.25
2018-12-31 -2.31
2018-09-30 -2.53
2018-06-30 -2.64
2018-03-31 -2.99
2017-12-31 -3.35
2017-09-30 -3.01
2017-06-30 -3.43
2017-03-31 -3.19
2016-12-31 -3.88

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NanoViricides will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of NNVC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. NanoViricides's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. NanoViricides's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess NanoViricides's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NanoViricides has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NanoViricides performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NanoViricides's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NanoViricides does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare NanoViricides's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NanoViricides's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
NanoViricides's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NanoViricides Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:NNVC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 -8.14 2.62 5.99
2019-06-30 -8.42 2.74 5.92
2019-03-31 -7.86 3.94 4.78
2018-12-31 -7.83 4.30 4.76
2018-09-30 -8.40 3.21 5.87
2018-06-30 -8.56 3.36 5.91
2018-03-31 -9.47 3.65 5.64
2017-12-31 -10.50 3.58 5.91
2017-09-30 -9.25 3.86 5.53
2017-06-30 -10.30 3.03 6.57
2017-03-31 -9.40 3.98 5.87
2016-12-31 -11.25 3.90 5.38
2016-09-30 -12.48 3.88 5.20
2016-06-30 -10.72 3.83 5.03
2016-03-31 -9.99 4.30 4.81
2015-12-31 -5.25 3.92 4.29
2015-09-30 -4.36 3.62 4.13
2015-06-30 -2.20 3.40 3.66
2015-03-31 -8.28 3.78 4.48
2014-12-31 -6.71 3.79 4.55
2014-09-30 -6.19 3.70 4.77
2014-06-30 -13.60 3.54 5.13
2014-03-31 -8.78 2.49 3.94
2013-12-31 -13.79 2.72 4.68
2013-09-30 -13.63 2.63 4.26
2013-06-30 -8.88 2.30 4.29
2013-03-31 -8.34 2.28 4.29
2012-12-31 -6.69 1.95 4.52

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NanoViricides has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NanoViricides has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NanoViricides improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NanoViricides's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NanoViricides has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NanoViricides's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NanoViricides's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NanoViricides's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • NanoViricides has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NanoViricides's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • NanoViricides has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NanoViricides Company Filings, last reported 2 months ago.

AMEX:NNVC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 9.13 0.00 0.87
2019-06-30 10.60 0.00 2.56
2019-03-31 12.72 0.00 4.24
2018-12-31 13.84 0.00 3.90
2018-09-30 15.98 0.00 6.08
2018-06-30 17.66 0.00 7.08
2018-03-31 19.15 0.00 10.62
2017-12-31 15.92 0.00 12.05
2017-09-30 18.52 4.20 13.51
2017-06-30 20.32 3.96 15.10
2017-03-31 22.41 3.73 16.16
2016-12-31 19.15 9.44 19.30
2016-09-30 20.23 9.01 21.91
2016-06-30 23.05 8.61 24.16
2016-03-31 23.98 8.23 25.60
2015-12-31 28.38 7.86 28.24
2015-09-30 30.71 7.51 29.48
2015-06-30 31.79 7.18 31.47
2015-03-31 31.86 6.87 33.92
2014-12-31 30.51 6.57 35.26
2014-09-30 32.19 6.28 41.12
2014-06-30 23.37 9.04 36.70
2014-03-31 32.03 3.89 33.27
2013-12-31 10.21 3.74 16.95
2013-09-30 11.75 3.60 19.20
2013-06-30 8.01 3.47 13.92
2013-03-31 10.12 3.34 15.46
2012-12-31 14.21 0.00 13.88
  • NanoViricides has no debt.
  • NanoViricides has no debt compared to 5 years ago when it was 19.5%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NanoViricides has less than a year of cash runway based on current free cash flow.
  • NanoViricides has less than a year of cash runway if free cash flow continues to reduce at historical rates of -2.5% each year.
X
Financial health checks
We assess NanoViricides's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NanoViricides has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NanoViricides's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NanoViricides dividends.
If you bought $2,000 of NanoViricides shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NanoViricides's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NanoViricides's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AMEX:NNVC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1961 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AMEX:NNVC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NanoViricides has not reported any payouts.
  • Unable to verify if NanoViricides's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NanoViricides's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NanoViricides has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NanoViricides's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NanoViricides afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NanoViricides has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NanoViricides's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Anil Diwan
COMPENSATION $589,038
AGE 60
CEO Bio

Dr. Anil R. Diwan, Ph.D., has been the Executive Chairman and President of NanoViricides, Inc. since June 1, 2005 and serves as its Secretary. Dr. Diwan has been Acting Chief Executive Officer of NanoViricides, Inc. Dr. Diwan served as the Chief Executive Officer of All Excel, Inc. since 1995 and TheraCour Pharma, Inc. since 2004. He is the original inventor of the technologies licensed to NanoViricides Inc. as well as the TheraCour polymeric micelle technologies and products based on them. Since 1992, he has researched and developed TheraCour nanomaterials. Dr. Diwan has extensive product development experience while raising financing from collaborations, SBIR grants, and other revenues. He has extensive experience in a number of bio-pharmaceutical, biosciences and biomedical fields and technologies that leads to his novel, integrative approach in solving problems with low costs, high innovation and world-leading feature sets. Dr. Diwan is the inventor, developer and principal investor of TheraCour technologies. He has over 18 years of Bio-Pharmaceuticals R&D experience with 12 years as an entrepreneur. He has been a Director of All Excel, Inc. since 1995 and TheraCour Pharma, Inc. since 2004. He holds a US patent on his older polymeric micelle technologies, with his colleagues at University of Massachusetts. Dr. Diwan has continued to work further in the field, to develop nanomaterials that are capable of multi-specific multi-targeting of viruses and at the same time capable of encapsulating active pharmaceutical ingredients (API) in industry-leading payload capacities. He has held several scholastic distinctions, including an All-India 9th rank on the Joint Entrance Examination of all IIT's. Dr. Diwan holds a Ph.D. in Biochemical Engineering from Rice University, TX in 1986 and B.S. degree in Chemical Engineering from Indian Institute of Technology (IIT) Bombay in 1980 and has consistently held high scholastic ranks and honors.

CEO Compensation
  • Anil's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Anil's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the NanoViricides management team in years:

1.9
Average Tenure
63
Average Age
  • The average tenure for the NanoViricides management team is less than 2 years, this suggests a new team.
Management Team

Anil Diwan

TITLE
Executive Chairman
COMPENSATION
$589K
AGE
60

Meeta Vyas

TITLE
Chief Financial Officer
COMPENSATION
$154K
AGE
60
TENURE
6.6 yrs

Irach Taraporewala

TITLE
Consultant
COMPENSATION
$431K
AGE
63
TENURE
0.8 yrs

Randy Barton

TITLE
Chief Scientific Officer & Chief Regulatory Officer
AGE
72

Eugene Seymour

TITLE
Chief Executive Officer Emeritus
COMPENSATION
$2M
AGE
78
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the NanoViricides board of directors in years:

11.5
Average Tenure
68
Average Age
  • The average tenure for the NanoViricides board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Paul Marks

TITLE
Chairman of Scientific Advisory Board
AGE
92
TENURE
14.5 yrs

Anil Diwan

TITLE
Executive Chairman
COMPENSATION
$589K
AGE
60
TENURE
14.5 yrs

Stanley Glick

TITLE
Independent Director
COMPENSATION
$39K
AGE
82
TENURE
7.5 yrs

James Sapirstein

TITLE
Independent Director
COMPENSATION
$31K
AGE
58
TENURE
1.1 yrs

Harmon Aronson

TITLE
Member of Scientific Advisory Board
AGE
76
TENURE
14.5 yrs

Thomas Lentz

TITLE
Member of Scientific Advisory Board
TENURE
11.5 yrs

Mark Day

TITLE
Independent Director
COMPENSATION
$14K
AGE
47
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess NanoViricides's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NanoViricides has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Do Institutions Own NanoViricides, Inc. (NYSEMKT:NNVC) Shares?

We can see that NanoViricides does have institutional investors; and they hold 5.9% of the stock. … Insider Ownership Of NanoViricides The definition of company insiders can be subjective, and does vary between jurisdictions. … Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual.

Simply Wall St -

What Kind Of Share Price Volatility Should You Expect For NanoViricides, Inc. (NYSEMKT:NNVC)?

(NYSEMKT:NNVC), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Do Directors Own NanoViricides, Inc. (NYSEMKT:NNVC) Shares?

Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … NanoViricides is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Who Are The Largest Shareholders In NanoViricides Inc (NYSEMKT:NNVC)?

In this analysis, my focus will be on developing a perspective on NanoViricides Inc’s (NYSEMKT:NNVC) latest ownership structure, a less discussed, but important factor. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.

Simply Wall St -

Who Are NanoViricides Inc's (NYSEMKT:NNVC) Major Shareholders?

Today, I will be analyzing NanoViricides Inc’s (AMEX:NNVC) recent ownership structure, an important but not-so-popular subject among individual investors. … Private Company Ownership Another important group of owners for potential investors in NNVC are private companies that hold a stake of 19.60% in NNVC. … Thus, investors should dig deeper into NNVC's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: Institutional ownership level and composition in NNVC is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

Who Owns Most Of NanoViricides Inc (NYSEMKT:NNVC)?

This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … With this size of ownership in NNVC, this ownership class can affect the company's business strategy. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: Institutional ownership level and composition in NNVC is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

How Should You Think About NanoViricides Inc's (NYSEMKT:NNVC) Risks?

If you are looking to invest in NanoViricides Inc’s (AMEX:NNVC), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … There are two types of risks that affect the market value of a listed company such as NNVC. … Based on this beta value, NNVC appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market.

Simply Wall St -

Is NanoViricides Inc's (NYSEMKT:NNVC) CEO Paid Enough Relative To Peers?

View our latest analysis for NanoViricides Did Seymour create value? … NNVC can create value to shareholders by increasing its profitability, which in turn is reflected into the share price and the investor's ability to sell their shares at higher capital gains. … Normally I would look at market cap and earnings as a proxy for performance, however, NNVC's negative earnings lower the usefulness of my formula.

Simply Wall St -

Have Investors Already Priced In Healthcare Growth For NanoViricides Inc (NNVC)?

This rate is larger than the growth rate of the US stock market as a whole. … In the previous year, the industry saw growth of 8.45%, though still underperforming the wider US stock market. … AMEX:NNVC PE PEG Gauge Nov 21st 17 The biotech industry is trading at a PE ratio of 27x, higher than the rest of the US stock market PE of 22x.

Simply Wall St -

Is NanoViricides Inc's (NNVC) Balance Sheet Strong Enough To Weather A Storm?

We can test the impact of these adverse events by looking at whether cash from its current operations can pay back its current debt obligations. … Can NNVC meet its short-term obligations with the cash in hand? … In times of adverse events, NNVC may need to liquidate its short-term assets to pay these immediate obligations.

Simply Wall St -

Company Info

Description

NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of all types of Dengue viruses; and HIVCide that is an escape-resistant anti-HIV nanoviricide. In addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

Details
Name: NanoViricides, Inc.
NNVC
Exchange: AMEX
Founded: 2005
$8,054,860
3,854,000
Website: http://www.nanoviricides.com
Address: NanoViricides, Inc.
1 Controls Drive,
Shelton,
Connecticut, 06484,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX NNVC Common Stock NYSE MKT LLC US USD 02. Jun 2005
DB NV3N Common Stock Deutsche Boerse AG DE EUR 02. Jun 2005
Number of employees
Current staff
Staff numbers
17
NanoViricides employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/12/14 00:16
End of day share price update: 2019/12/13 00:00
Last estimates confirmation: 2019/08/23
Last earnings filing: 2019/11/15
Last earnings reported: 2019/09/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.